Does Rallies show 13F holders for IRON?

Yes. Rallies tracks hedge fund and 13F ownership data for IRON, including fund names, share counts, latest tracked quarter, and position changes when available.

Is IRON research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IRON. It does not provide personalized investment advice.

IRON (Disc Medicine, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Disc Medicine, Inc. Common Stock (IRON) is a publicly traded Healthcare sector company. As of May 20, 2026, IRON trades at $66.94 with a market cap of $2.55B and a P/E ratio of -11.02. IRON moved +4.67% today. Year to date, IRON is -14.75%; over the trailing twelve months it is +33.85%. Its 52-week range spans $30.82 to $99.50. Analyst consensus is strong buy with an average price target of $98.22. Rallies surfaces IRON's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns IRON stock?

Hedge funds tracked by Rallies that own IRON include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Disc Medicine, Inc. Common Stock.

IRON Key Metrics

Key financial metrics for IRON
Metric	Value
Price	$66.94
Market Cap	$2.55B
P/E Ratio	-11.02
EPS	$-6.01
Dividend Yield	0.00%
52-Week High	$99.50
52-Week Low	$30.82
Volume	381.69K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-212.18M
Gross Margin	0.00%

Top Hedge Funds Holding IRON

Orbimed Advisors holds 1.07M shares of IRON, changed +0.00% as of Mar 31, 2026.

Latest IRON News

Disc Medicine Completes 183-Patient Phase 3 Enrollment, Holds $730M Cash Runway — May 5, 2026
Disc Medicine Expands Phase 3 APOLLO Trial to 183 Patients, Data Due Q4 2026 — Mar 26, 2026
Disc Medicine Posts $791 M Cash, FDA CRL for Bitopertin, Q4 2026 Readout — Feb 26, 2026
Disc Medicine Shares Drop 22% After FDA CRL on Bitopertin Approval — Feb 17, 2026
Disc Medicine Receives FDA CRL, Eyes Q4 2026 APOLLO Phase 3 Topline — Feb 13, 2026

Recent IRON Insider Trades

Franchi Jean M. sold 6.26K (~$433.23K) on Apr 14, 2026.
Savage William Jacob sold 3.53K (~$233.47K) on Apr 13, 2026.
Savage William Jacob sold 2.20K (~$146.98K) on Apr 13, 2026.

IRON Analyst Consensus

10 analysts cover IRON: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $98.22.

Common questions about IRON

Who owns IRON stock?: Hedge funds tracked by Rallies that own IRON include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Disc Medicine, Inc. Common Stock.
Does Rallies show 13F holders for IRON?: Yes. Rallies tracks hedge fund and 13F ownership data for IRON, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IRON research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IRON. It does not provide personalized investment advice.